These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21050790)

  • 1. [Reporting and notification of transfusion serious adverse events in France].
    Daurat G
    Transfus Clin Biol; 2010 Dec; 17(5-6):362-5. PubMed ID: 21050790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [European regulation on blood and blood components].
    Sandid I
    Transfus Clin Biol; 2010 Dec; 17(5-6):310-4. PubMed ID: 21050786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recipients adverse reactions: guidance supports].
    Bazin A
    Transfus Clin Biol; 2010 Dec; 17(5-6):366-74. PubMed ID: 21051267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Review of the main haemovigilance systems in the world].
    Faber JC
    Transfus Clin Biol; 2009 May; 16(2):86-92. PubMed ID: 19442556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Seventeen years of haemovigilance in France: assessment and outlook].
    Carlier M; Vo Mai MP; Fauveau L; Ounnoughene N; Sandid I; Renaudier P
    Transfus Clin Biol; 2011 Apr; 18(2):140-50. PubMed ID: 21474356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality validation of data in national haemovigilance systems in Europe: report of a survey on current state of practice.
    Wiersum-Osselton JC; Faber JC; Politis C; Brand A; van der Bom JG; Schipperus MR
    Vox Sang; 2013 Apr; 104(3):214-7. PubMed ID: 23061879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [French European military haemovigilance guidelines].
    Sailliol A; Clavier B; Cap A; Ausset S
    Transfus Clin Biol; 2010 Dec; 17(5-6):315-7. PubMed ID: 21051263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemovigilance: an effective tool for improving transfusion practice.
    de Vries RR; Faber JC; Strengers PF;
    Vox Sang; 2011 Jan; 100(1):60-7. PubMed ID: 21175656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Transfusion transmitted bacterial infectious (TTBI) with blood component accountability score 2: Retrospective analysis of the French e-fit database 2000-2007. Groupe de travail–validation des IBTT (Working group for validation of transfusion-transmitted bacterial infections)].
    Delbosc A; Lafeuillade B; Petermann R; Eb F; Ounnoughene N
    Transfus Clin Biol; 2011 Feb; 18(1):26-35. PubMed ID: 21310643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [What is the use of hemovigilance?].
    Quaranta JF; Canivet N
    Transfus Clin Biol; 1998 Dec; 5(6):415-21. PubMed ID: 9894333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Why is it necessary to review the December 15th 2003 circular relative to the transfusion act?].
    Lassale B; Besse-Moreau M; Aullen JP
    Transfus Clin Biol; 2014 Nov; 21(4-5):223-6. PubMed ID: 25267206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Delayed adverse reactions to blood donation: From haemovigilance data to specific studies].
    Py JY; Durieux S; Barnoux M; Sapey T
    Transfus Clin Biol; 2016 Nov; 23(4):233-239. PubMed ID: 27769684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adverse unidentified transfusion reactions in five French regions: analysis, results, propositions].
    Aullen JP; Delbosc A; Ferrer Le Coeur F; Rivière P; Schlanger S;
    Transfus Clin Biol; 2010 Feb; 17(1):20-7. PubMed ID: 20153674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The German Haemovigilance System--reports of serious adverse transfusion reactions between 1997 and 2007.
    Keller-Stanislawski B; Lohmann A; Günay S; Heiden M; Funk MB
    Transfus Med; 2009 Dec; 19(6):340-9. PubMed ID: 19725904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Online reporting system for transfusion-related adverse events to enhance recipient haemovigilance in Japan: a pilot study.
    Odaka C; Kato H; Otsubo H; Takamoto S; Okada Y; Taneichi M; Okuma K; Sagawa K; Hoshi Y; Tasaki T; Fujii Y; Yonemura Y; Iwao N; Tanaka A; Okazaki H; Momose SY; Kitazawa J; Mori H; Matsushita A; Nomura H; Yasoshima H; Ohkusa Y; Yamaguchi K; Hamaguchi I
    Transfus Apher Sci; 2013 Feb; 48(1):95-102. PubMed ID: 22954634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Blood transfusion surveillance: organization and results].
    Rebibo D; Morel P; Hauser L; Hervé P
    Rev Prat; 2001 Jun; 51(12):1332-6. PubMed ID: 11503507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The French haemovigilance system.
    Debeir J; Noel L; Aullen J; Frette C; Sari F; Mai MP; Cosson A
    Vox Sang; 1999; 77(2):77-81. PubMed ID: 10516551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The blood donors' haemovigilance in France].
    Ounnoughene N; Sandid I; Carlier M; Joussemet M; Ferry N
    Transfus Clin Biol; 2013 May; 20(2):182-92. PubMed ID: 23587615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What to do in case of adverse event in recipient at the French National Blood Service?].
    Leconte des Floris MF; Pourcelot L; Hauser L; Hervé I; Waller C; Bardiaux L; Morel P
    Transfus Clin Biol; 2012 Nov; 19(4-5):182-6. PubMed ID: 23006955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eight years with haemovigilance in Norway. What have we learnt?
    Steinsvåg CT; Espinosa A; Flesland Ø
    Transfus Apher Sci; 2013 Dec; 49(3):548-52. PubMed ID: 24157220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.